Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by RTW Investments LP

RTW Investments LP lessened its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 42.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,672,630 shares of the company's stock after selling 6,273,790 shares during the period. RTW Investments LP owned approximately 4.23% of Taysha Gene Therapies worth $15,004,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of TSHA. Ground Swell Capital LLC acquired a new position in Taysha Gene Therapies in the 4th quarter valued at about $25,000. Cibc World Markets Corp acquired a new position in shares of Taysha Gene Therapies in the fourth quarter valued at approximately $28,000. E Fund Management Co. Ltd. acquired a new position in shares of Taysha Gene Therapies in the fourth quarter valued at approximately $31,000. Hsbc Holdings PLC lifted its holdings in Taysha Gene Therapies by 65.6% during the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock worth $36,000 after buying an additional 8,076 shares in the last quarter. Finally, AXQ Capital LP purchased a new position in Taysha Gene Therapies in the 4th quarter valued at approximately $39,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on TSHA. JMP Securities reiterated a "market outperform" rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Needham & Company LLC reiterated a "buy" rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. Canaccord Genuity Group increased their price objective on Taysha Gene Therapies from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Friday. Chardan Capital restated a "buy" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $6.57.

Taysha Gene Therapies Stock Up 3.3%

Shares of Taysha Gene Therapies stock traded up $0.09 during trading hours on Monday, hitting $2.79. The company had a trading volume of 3,231,459 shares, compared to its average volume of 2,857,039. The company's 50-day moving average is $1.72 and its two-hundred day moving average is $1.82. Taysha Gene Therapies, Inc. has a twelve month low of $1.05 and a twelve month high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The company has a market cap of $572.10 million, a P/E ratio of 4.43 and a beta of 0.90.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $2.30 million for the quarter, compared to analyst estimates of $1.48 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. During the same quarter last year, the company posted ($0.10) earnings per share. Analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.